Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
Department of Ophthalmology, University of Medicine, Cluj-Napoca - Romania.
Dan
D
Călugăru
Department of Ophthalmology, University of Medicine, Cluj-Napoca - Romania.
Mihai
M
Călugăru
D020533:Angiogenesis Inhibitors; D020256:Choroidal Neovascularization; D006801:Humans; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab